Skip to main content
Novacyt logo

Novacyt — Investor Relations & Filings

Ticker · ALNOV ISIN · FR0010397232 LEI · 213800BWAC2BF295EG28 PA Manufacturing
Open in API
Filings indexed 1,101 across all filing types
Latest filing 2024-10-31 Board/Management Inform…
Country FR France
Listing PA ALNOV

About Novacyt

https://novacyt.com/

Novacyt is an international molecular diagnostics company that provides a broad portfolio of integrated technologies and services. The company's core activities include the design, development, manufacturing, and commercialization of in vitro and molecular diagnostic tests, with a specialization in real-time PCR (qPCR) kits and reagents. Novacyt's solutions are applied across various markets, including clinical diagnostics for human health, with a focus on infectious diseases and oncology, as well as animal health and food safety. The company also offers custom development services, contract manufacturing, and pharmaceutical research services such as whole genome sequencing.

Recent filings

Filing Released Lang Actions
Directorate Change
Board/Management Information Classification · 100% confidence The document explicitly announces the 'Directorate Change' regarding the appointment of Dr Ian Gilham as a Non-Executive Director. This type of announcement, detailing changes in the company's board of directors or senior management, directly corresponds to the definition of Board/Management Information. Filing Definition 4: Board/Management Information (Code: MANG) - Description: Announcement of changes in the company's board of directors or senior management.
2024-10-31 English
Certification IVDR obtenue pour le test de référence Yourgene® de la mucoviscidose
Regulatory Filings Classification · 100% confidence The document is a press release from Novacyt S.A. dated October 17, 2024, announcing that they have received IVDR certification for their Yourgene® Cystic Fibrosis reference test. This type of announcement, detailing a specific operational achievement, regulatory milestone, or product update, is characteristic of a general corporate announcement or regulatory filing that doesn't fit the specific financial report categories (like 10-K, ER, IR). Since it is a specific, non-financial operational update (regulatory certification), and it is not a proxy statement (DEF 14A), director dealing (DIRS), or a simple announcement of a report publication (RPA), the most appropriate general category for a specific, non-standard regulatory/operational update is 'Regulatory Filings' (RNS), as it serves as a catch-all for important company news that isn't strictly financial reporting or management change.
2024-10-17 French
IVDR accreditation
Regulatory Filings Classification · 100% confidence The document is a formal announcement disseminated via RNS (Regulatory News Service), indicated by the 'RNS Number' and the concluding boilerplate text referencing RNS and the London Stock Exchange. The content announces a specific operational achievement: receiving IVDR accreditation for a diagnostic assay. This type of announcement, which is a material update but not a full financial report (10-K, IR), management change (MANG), or dividend declaration (DIV), fits best under the general category for regulatory announcements that don't have a more specific code. Since it is a formal, non-financial regulatory update distributed through the official channel, it is classified as a Regulatory Filing (RNS). It is not an Earnings Release (ER), Interim Report (IR), or a Report Publication Announcement (RPA) because it is reporting a specific event/achievement, not just announcing the publication of a larger report.
2024-10-17 English
Closure of IT-IS International
Regulatory Filings Classification · 100% confidence The document begins with an 'RNS Number' and is dated October 8, 2024. It announces a specific corporate action: the closure of a subsidiary (IT-IS International) and details the financial implications (restructuring charge, impact on EBITDA) and ongoing legal matters (IP infringement dispute). This type of announcement, which conveys material, non-public information to the market via an official news service (RNS), is typically classified as a general regulatory announcement. Since the content is not a full financial report (10-K, IR), an earnings release (ER), a management discussion (MDA), or a specific insider trade (DIRS), the most appropriate classification is the general regulatory filing category, RNS, as it is distributed through the RNS system and contains material corporate news.
2024-10-08 English
Closure of IT-IS International
Delisting Announcement Classification · 99% confidence The document announces a specific corporate action: the closure of a subsidiary (IT-IS International) and details the financial implications (restructuring charge, discontinued operation treatment under IFRS 5) and strategic rationale. It also mentions an ongoing IP dispute and contains a statement confirming it includes 'inside information for the purposes of Article 7 of Regulation (EU) 596/2014'. This type of announcement, detailing significant operational changes, financial impacts, and strategic decisions, is typically classified as a Regulatory Filing (RNS) if it doesn't fit a more specific category like Director's Dealing (DIRS) or Capital Change (CAP). Since it is a material, non-periodic announcement concerning the business structure and financial outlook, and it is not a full report (like 10-K or IR), nor a management discussion (MDA), nor an earnings release (ER), the most appropriate general regulatory announcement category is RNS, as it is a broad disclosure of material, non-scheduled information.
2024-10-08 English
Fermeture d’IT-IS International
Regulatory Filings Classification · 100% confidence The document is a formal announcement dated October 8, 2024, regarding the closure of a subsidiary (IT-IS International) and the associated financial implications (restructuring costs, impact on EBITDA, treatment as discontinued operation under IFRS 5). It also mentions the preservation of Intellectual Property related to an ongoing legal dispute with Roche Diagnostics. This type of announcement, detailing a significant operational change, restructuring, and its financial impact, is typically classified as a corporate event disclosure. Since it is not a full annual report (10-K), a quarterly report (IR), an earnings release (ER), or a specific management discussion (MDA), and it relates to significant corporate actions and legal matters, it fits best under the general category for significant corporate news or regulatory filings. Given the content focuses on a major operational decision, restructuring, and ongoing litigation, it is most closely aligned with a general regulatory announcement or a specific corporate action disclosure. Since there isn't a specific code for 'Restructuring Announcement' or 'Operational Update', and it contains privileged information ('informations privilégiées'), it functions as a material disclosure. In the absence of a more specific fit, and considering it's a formal press release detailing strategic changes, it falls under the broad Regulatory Filings (RNS) category, or potentially a Legal Proceedings Report (LTR) due to the mention of the Roche litigation, but the primary focus is the closure and financial impact. Given the context of corporate actions, RNS is the most appropriate general regulatory disclosure category for material, non-standardized news.
2024-10-08 French

Browse filings by year

14 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.